Network-based Drug Repurposing for Human Coronavirus

Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng

confirmed the mammalian target of rapamycin complex 1 (mTORC1) as the key factor in regulating various viruses' replications, including Andes orthohantavirus and coronavirus [45, 46] . Sirolimus (Z = -2.35 and GSEA score = 3), an inhibitor of mammalian target of rapamycin (mTOR), was reported to effectively block viral protein expression and virion release effectively [47] . Indeed, the latest study revealed the clinical application: sirolimus reduced MERS-CoV infection by over 60% [48] . Moreover, sirolimus usage in managing patients with severe H1N1 pneumonia and acute respiratory failure can improve those patients' prognosis significantly [47] . Mercaptopurine (Z = -2.44 and GSEA score = 1), an antineoplastic agent with immunosuppressant property, has been used to treat cancer since the 1950s and expanded its application to several autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease [49] . Mercaptopurine has been reported as a selective inhibitor of both . CC-BY-NC 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.